

Aqua Fem's Patented AF Compound Shows Breakthrough Gains in Sperm Motility

Novel infertility treatment compound could improve outcomes in IVF, IUI, and natural conception by enhancing sperm motility

The logo for Aqua Fem, with "AQUA" and "FEM" in a bold, blue, sans-serif font.

CHARLESTON, SC, UNITED STATES,

September 3, 2025 /EINPresswire.com/ -- Aqua Fem, LLC, a reproductive health innovation company, today announced compelling new data from independent testing showing that [its patented AF compound](#) significantly increases sperm motility — a key factor in conception.

Designed for use in assisted reproductive technologies (ART) such as in vitro fertilization (IVF) and intrauterine insemination (IUI), AF also has potential as an over-the-counter option for couples trying to conceive naturally.

“

Sperm motility is one of the most important predictors of fertilization success, and AF's ability to reliably boost motility at this scale could meaningfully impact patients struggling to conceive.”

*Eric Lacy PhD, Co-Founder
and Chief Scientific Officer of
Aqua Fem*

The latest study analyzed sperm samples from three different donors, collected months apart, to assess reproducibility. Results showed:

— 200%, 212%, and 600% increases in motility compared to baseline when treated with AF in its patented hetero-dimeric form.

These findings build upon earlier testing, which recorded increases averaging 700% in prior donor samples. The new data confirms a consistent, statistically significant

enhancement of motility, strengthening the evidence for AF's potential as an affordable, accessible male fertility solution.

"These results are a critical step forward in our mission to improve ART outcomes and expand fertility treatment options worldwide," said Eric Lacy PhD, Co-Founder and Chief Scientific Officer of Aqua Fem. "Sperm motility is one of the most important predictors of fertilization success, and AF's ability to reliably boost motility at this scale could meaningfully impact patients struggling with infertility."

AF, developed from a marine-derived compound, is currently being evaluated for integration into

sperm preparation media in fertility clinics, as well as potential over-the-counter applications for at-home use. Aqua Fem is [seeking to sell the patented AF intellectual property](#) to leading fertility industry partners who can bring the technology to market and maximize its impact on global fertility care.

For more information, [visit www.aquafemlabs.com](http://www.aquafemlabs.com).

Kara DeMaio

Aqua Fem LLC

cco@aquafemlabs.com

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/845325260>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.